Altimmune

PharmAthene, Altimmune merge

Friday, January 20, 2017

PharmAthene and Altimmune, a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune’s current investors include Novartis Venture Fund, HealthCap, Truffle Capital and Redmont Capital. The combined company will be a fully-integrated and diversified immunotherapeutics company with four clinical stage and one preclinical stage programs. The proposed transaction does not affect PharmAthene’s previously announced special one-time cash dividend of $2.91 per share of common stock.

[Read More]

Altimmune receives $120M BARDA contract for Anthrax vaccine candidate Nasoshield

Wednesday, August 3, 2016

Altimmune, a clinical stage immunotherapeutic company, was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund the clinical development of NasoShield, its first-in-class anthrax vaccine candidate. Under BARDA contract HHSO100201600008C, Altimmune has been awarded $14.3 million under the base contract to fund its phase I trial for NasoShield, and options to receive up to an additional $105.9 million to fund further preclinical, clinical and manufacturing development activities. 

[Read More]